INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 101 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is 1.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $169,982 | +31.6% | 807,517 | 0.0% | 0.00% | – |
| Q1 2023 | $129,202 | +28739.7% | 807,517 | 0.0% | 0.00% | – |
| Q4 2022 | $448 | -100.0% | 807,517 | -7.1% | 0.00% | – |
| Q3 2022 | $1,034,000 | +88.3% | 869,575 | 0.0% | 0.00% | – |
| Q2 2022 | $549,000 | -66.4% | 869,575 | -39.3% | 0.00% | – |
| Q1 2022 | $1,632,000 | -55.6% | 1,431,624 | -12.3% | 0.00% | – |
| Q4 2021 | $3,673,000 | -38.1% | 1,632,561 | -5.9% | 0.00% | -100.0% |
| Q3 2021 | $5,930,000 | +40.2% | 1,734,032 | +22.6% | 0.00% | 0.0% |
| Q2 2021 | $4,230,000 | +90.4% | 1,414,918 | +105.6% | 0.00% | – |
| Q1 2021 | $2,222,000 | +173.6% | 688,169 | +79.6% | 0.00% | – |
| Q4 2020 | $812,000 | +86.7% | 383,077 | +3.0% | 0.00% | – |
| Q3 2020 | $435,000 | +29.5% | 371,860 | 0.0% | 0.00% | – |
| Q2 2020 | $336,000 | +10.5% | 371,860 | +2.3% | 0.00% | – |
| Q1 2020 | $304,000 | -56.4% | 363,617 | -50.0% | 0.00% | – |
| Q4 2019 | $698,000 | +86.6% | 727,234 | +100.0% | 0.00% | – |
| Q3 2019 | $374,000 | -42.8% | 363,617 | 0.0% | 0.00% | – |
| Q2 2019 | $654,000 | -1.7% | 363,617 | +2.7% | 0.00% | – |
| Q1 2019 | $665,000 | -20.3% | 354,047 | -50.0% | 0.00% | – |
| Q4 2018 | $834,000 | -13.0% | 708,094 | +100.0% | 0.00% | – |
| Q3 2018 | $959,000 | +46.2% | 354,047 | +3.0% | 0.00% | – |
| Q2 2018 | $656,000 | -4.0% | 343,843 | +5.6% | 0.00% | – |
| Q1 2018 | $683,000 | +3.5% | 325,567 | 0.0% | 0.00% | – |
| Q4 2017 | $660,000 | +86.4% | 325,567 | +22.2% | 0.00% | – |
| Q3 2017 | $354,000 | -15.9% | 266,503 | -0.6% | 0.00% | – |
| Q2 2017 | $421,000 | -62.2% | 268,198 | -22.3% | 0.00% | – |
| Q1 2017 | $1,114,000 | +150.3% | 345,366 | +4.5% | 0.00% | – |
| Q4 2016 | $445,000 | -10.6% | 330,361 | +3.4% | 0.00% | – |
| Q3 2016 | $498,000 | +18.9% | 319,410 | +1.3% | 0.00% | – |
| Q2 2016 | $419,000 | -76.4% | 315,401 | -6.4% | 0.00% | -100.0% |
| Q1 2016 | $1,774,000 | -25.9% | 336,935 | +10.4% | 0.00% | 0.0% |
| Q4 2015 | $2,394,000 | -22.3% | 305,057 | -16.3% | 0.00% | -50.0% |
| Q3 2015 | $3,080,000 | -20.9% | 364,678 | +2.5% | 0.00% | 0.0% |
| Q2 2015 | $3,896,000 | -14.0% | 355,894 | +9.9% | 0.00% | -33.3% |
| Q1 2015 | $4,528,000 | -20.6% | 323,971 | -4.0% | 0.00% | 0.0% |
| Q4 2014 | $5,701,000 | +78.9% | 337,641 | +42.2% | 0.00% | +50.0% |
| Q3 2014 | $3,187,000 | +6.5% | 237,494 | +1.1% | 0.00% | 0.0% |
| Q2 2014 | $2,993,000 | +11.3% | 234,971 | +3.9% | 0.00% | 0.0% |
| Q1 2014 | $2,689,000 | -10.5% | 226,159 | +3.9% | 0.00% | 0.0% |
| Q4 2013 | $3,006,000 | -12.6% | 217,727 | +10.5% | 0.00% | -33.3% |
| Q3 2013 | $3,439,000 | +3.5% | 197,096 | -3.6% | 0.00% | 0.0% |
| Q2 2013 | $3,323,000 | – | 204,463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |